权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Effect of Artificially Sweetened Beverages on Diabetes Control in Adults with Type 2 Diabetes

人工甜味饮料对成人 2 型糖尿病患者糖尿病控制的影响

基本信息

批准号：
10163173
负责人：
Andrew Owen Odegaard
金额：
$ 64.21万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-15 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10163173
关键词：
Address Adult Artificial Sweeteners Basic Science Behavior Beverages Body Weight decreased Calories Cardiovascular Diseases Caring Categories Chronic Disease Clinical Clinical Research Complement Consumption Data Desire for food Diabetes Mellitus Diet Dietary intake Dietetics Glycosylated Hemoglobin Glycosylated hemoglobin A Health Hormones Hour Intake Intervention Knowledge Link Measures Metabolic Metabolic syndrome Non-Insulin-Dependent Diabetes Mellitus Nutrient Obesity Obesity Epidemic Outcome Patients Play Population Population Research Positioning Attribute Primary Prevention Public Health Publications Randomized Randomized Clinical Trials Recommendation Renal function Reporting Research Risk Risk Factors Role Running Satiation Secondary Prevention Source Taste preferences Testing Twin Multiple Birth Water Water consumption arm cardiometabolic risk clinical risk clinically significant diabetes control dietary disorder risk evidence base experience food environment glycemic control gut microbiome improved interest microbiome composition pilot trial preference primary outcome randomized trial recruit scientific organization sugar sweet taste perception sweetened beverage

项目摘要

PROJECT SUMMARY Diet beverages sweetened with artificial sweeteners (AS) occupy a unique category in the food environment as they are a source of intensely sweet taste with no calories or nutrients. Diet beverages are the single largest contributor to AS intake in the U.S. diet, and consumption of diet beverages has significantly increased over the past 30 plus years in concert with the twin epidemics of obesity and type 2 diabetes. A burgeoning body of basic, clinical, and population research suggests that diet beverages are linked with obesity, decline in kidney function, and increased risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease. Other developing research has suggested diet beverages and the AS that sweeten them may alter gut hormones, the gut microbiome, taste preferences, satiety, and overall dietary intake, thus providing plausible mechanisms whereby disease risk may be altered. These initial reports, and related hyperbolic media coverage, have sparked both scientific and public interest in the role that diet beverages may play in health. Despite this budding framework of knowledge, the evidence base is largely uninformed by randomized clinical trials testing whether intake of diet beverages impacts measures of clinical risk. Furthermore, an issue central to this topic is the lack of research addressing the population with diabetes, perhaps the most important population with respect to diet beverage intake. People with diabetes are the highest consumers of diet beverages, tending to consume them as a replacement for dietary sources of sugar, especially in place of sugar-sweetened beverages. This behavior has been endorsed by dietetic and scientific organizations, and diet beverages are marketed as being synonymous with better health, suitable for weight loss, and thus advantageous for diabetes control. The underlying public health concern is that there are few data to support or refute the benefit or harm of habitual diet beverage consumption by people with diabetes. To begin addressing this important scientific gap we propose to test the effect of diet beverage intake on diabetes control parameters in free-living adults with type 2 diabetes in a randomized, two arm parallel trial with a run-in period of 2-weeks and an active intervention period of 12-weeks. We will recruit 240 patients with type 2 diabetes who are usual consumers of commercial diet beverages and randomize them to receive and consume either: 1) A commercial diet beverage of choice (3 servings or 24 oz. daily); or 2) Unflavored bottled water of choice (sparkling or plain) (3 servings or 24 oz. daily). The primary outcome will be a central measure of clinical diabetes control in glycated hemoglobin (HbA1c), and we will also measure cardiometabolic risk and kidney function. Additionally, we will measure plausible mechanisms whereby diet beverage intake may alter risk by assessing the effect of diet beverage intake on the functional composition of the gut microbiome as well as usual dietary intake, appetite, and taste preferences.

项目总结